Volume 21, Number 2—February 2015
Research
Quantifying Reporting Timeliness to Improve Outbreak Control
Table 2
Effects of reducing reporting delays, by disease*
Effect | Hepatitis A | Hepatitis B | Measles | Mumps | Pertussis | Shigellosis |
---|---|---|---|---|---|---|
Current PIR1 (PIR1 at symptom onset) | 0.818 (0.480) | 0.907 (0.810) | 0.947 (0.495) | 0.901 (0.574) | 0.948 (0.322) | 0.960 (0.230) |
Current PIR2 (PIR2 at symptom onset) | 0.145 (0.019) | 0.456 (0.320) | 0.423 (0.006) | 0.273 (0.005) | 0.817 (0.067) | 0.836 (0.056) |
PIR2 reduction ratio by reducing delay in 1 d | 9.7% | 1.5% | 12.6% | 13.5% | 0.7% | 2.4% |
Reporting delay median needed for PIR2 = 1/R | 17 d | 42 d | 5 d | 8 d | 4.5 d | 3 d |
Reporting delay median needed for PIR2 = 1/R2 | 8 d | 1 d | 2 d | 3 d | Not possible | 1 d |
Underreporting beyond which outbreak control is not possible | 29% | 1.5% | 12% | 18% | 12% | 25% |
Reduction of vaccination coverage for herd immunity | 70% | 64% | 8% | 20% | 2% | 4% |
*PIR values at symptom onset show a theoretical minimum, achievable by stopping transmission instantly at symptom onset. PIR1, proportion of expected infections produced by an index case; PIR2, proportion of expected infections produced by each secondary case produced by a reported index case.
Page created: January 20, 2015
Page updated: January 20, 2015
Page reviewed: January 20, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.